Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00423852 · OUTCOME

Maximum Tolerated Dose of Ifosfamide

Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin · Source last updated 2016-05-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
mg/m2
Interval / dispersion
Not reported
Time frame
4 years

Groups in this outcome

Chemotherapy With Stem Cell Support

This is a phase I/II trial of sequential accelerated chemotherapy cycles with paclitaxel/ifosfamide and paclitaxel/ifosfamide and carboplatin administered with G-CSF and PBSC support. During phase I, carboplatin, ifosfamide, and paclitaxel will be dose escalated to determine the MTD. Additional patients will be enrolled in the Phase II portion of the study following the determination of the MTD of Ifosfamide and paclitaxel, to bring the total possible number of patients treated at the MTD to 38. filgrastim carboplatin ifosfamide paclitaxel autologous hematopoietic stem cell transplantation peripheral blood stem cell transplantation

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Chemotherapy With Stem Cell Support23

Reported measurements

Source class 1
Values in mg/m2 · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemotherapy With Stem Cell Support9990Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        9990
denoms
  1. counts
    1. group Id
      OG000
      value
      23
    units
    Participants
groups
  1. description
    This is a phase I/II trial of sequential accelerated chemotherapy cycles with paclitaxel/ifosfamide and paclitaxel/ifosfamide and carboplatin administered with G-CSF and PBSC support. During phase I, carboplatin, ifosfamide, and paclitaxel will be dose escalated to determine the MTD. Additional patients will be enrolled in the Phase II portion of the study following the determination of the MTD of Ifosfamide and paclitaxel, to bring the total possible number of patients treated at the MTD to 38. filgrastim carboplatin ifosfamide paclitaxel autologous hematopoietic stem cell transplantation peripheral blood stem cell transplantation
    id
    OG000
    title
    Chemotherapy With Stem Cell Support
param Type
NUMBER
reporting Status
POSTED
time Frame
4 years
title
Maximum Tolerated Dose of Ifosfamide
type
PRIMARY
unit Of Measure
mg/m2

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice